Chronic Myelomonocytic Leukemia - 30 Studies Found Completed : Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) : Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia < : 2010-01-12 : Drug: Azacitidine 100 mg / m(2 Completed : Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia : Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrom : 2007-03-20 : Drug: sunitinib malate Given orally Other Names: Active, not recruiting : Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) : Anemia Myelodysplastic Syndromes Chr : 2012-11-27 : Drug: Sotatercept Sotatercept Recruiting : SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) : Myelofibrosis Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic : 2015-11-18 : Drug: Azacitidine Azacitidine RECRUITING : Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia : Recurrent Chronic Myelomonocytic Leukemia : 2024-11-21 : Undergo collection of blood samples RECRUITING : Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm : Chronic Myelomonocytic Leukemia : 2024-11-21 : Undergo collection of blood and buccal samples NOT_YET_RECRUITING : Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. : Chronic Myelomonocytic Leukemia : 2024-11-21 : CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule der COMPLETED : Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents : Refractory Chronic Myelomonocytic Leukemia : 2024-11-21 : Given PO COMPLETED : Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents : Refractory Chronic Myelomonocytic Leukemia : 2024-11-21 : Given PO <<< Previous
